Tarsus Pharmaceuticals (TARS) Competitors

$62.48 -2.70 (-4.14%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$61.08 -1.40 (-2.25%)

As of 05/15/2026 05:00 PM Eastern

TARS vs. RDY, ABVX, CYTK, KRYS, and PRAX

Should you buy Tarsus Pharmaceuticals stock or one of its competitors? MarketBeat compares Tarsus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tarsus Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Abivax (ABVX), Cytokinetics (CYTK), Krystal Biotech (KRYS), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Dr. Reddy's Laboratories has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Dr. Reddy's Laboratories has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.17	$484.20M	$0.58	23.46
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 10 mentions for Tarsus Pharmaceuticals and 9 mentions for Dr. Reddy's Laboratories. Tarsus Pharmaceuticals' average media sentiment score of 0.71 beat Dr. Reddy's Laboratories' score of -0.25 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories currently has a consensus target price of $16.90, suggesting a potential upside of 24.22%. Tarsus Pharmaceuticals has a consensus target price of $90.67, suggesting a potential upside of 45.11%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Summary

Tarsus Pharmaceuticals beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Abivax?

Abivax (NASDAQ:ABVX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Abivax presently has a consensus target price of $137.15, indicating a potential upside of 19.75%. Tarsus Pharmaceuticals has a consensus target price of $90.67, indicating a potential upside of 45.11%. Given Tarsus Pharmaceuticals' higher possible upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Abivax has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Abivax. MarketBeat recorded 10 mentions for Tarsus Pharmaceuticals and 5 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat Tarsus Pharmaceuticals' score of 0.71 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tarsus Pharmaceuticals has higher revenue and earnings than Abivax. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A

Summary

Tarsus Pharmaceuticals beats Abivax on 10 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Tarsus Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Tarsus Pharmaceuticals currently has a consensus target price of $90.67, indicating a potential upside of 45.11%. Cytokinetics has a consensus target price of $98.55, indicating a potential upside of 29.93%. Given Tarsus Pharmaceuticals' higher possible upside, equities analysts clearly believe Tarsus Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Cytokinetics had 10 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 20 mentions for Cytokinetics and 10 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.71 beat Cytokinetics' score of 0.38 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tarsus Pharmaceuticals has higher revenue and earnings than Cytokinetics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A
Cytokinetics	$88.04M	107.20	-$784.96M	-$6.84	N/A

Summary

Tarsus Pharmaceuticals beats Cytokinetics on 11 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 10 mentions for Tarsus Pharmaceuticals and 9 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.04 beat Tarsus Pharmaceuticals' score of 0.71 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a net margin of 53.92% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Krystal Biotech's return on equity of 19.25% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Krystal Biotech presently has a consensus price target of $324.11, indicating a potential upside of 5.82%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 45.11%. Given Tarsus Pharmaceuticals' higher possible upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Krystal Biotech has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	23.20	$204.83M	$7.48	40.95
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A

Summary

Krystal Biotech beats Tarsus Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Praxis Precision Medicines has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

In the previous week, Praxis Precision Medicines had 13 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 23 mentions for Praxis Precision Medicines and 10 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.71 beat Praxis Precision Medicines' score of 0.21 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	4 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines currently has a consensus target price of $592.67, suggesting a potential upside of 73.00%. Tarsus Pharmaceuticals has a consensus target price of $90.67, suggesting a potential upside of 45.11%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe Praxis Precision Medicines is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Tarsus Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,117.09	-$303.27M	-$13.37	N/A
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A

Summary

Praxis Precision Medicines beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARS vs. The Competition

Export

Metric	Tarsus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.69B	$3.31B	$6.38B	$12.30B
Dividend Yield	N/A	2.34%	2.81%	5.30%
P/E Ratio	-54.81	18.34	20.62	25.25
Price / Sales	5.02	288.04	554.93	75.55
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	7.72	6.76	9.80	6.71
Net Income	-$66.42M	$24.40M	$3.57B	$336.00M
7 Day Performance	2.07%	4.14%	0.23%	0.12%
1 Month Performance	-7.08%	-4.80%	-2.54%	-0.18%
1 Year Performance	42.97%	62.87%	33.54%	30.62%

Tarsus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARS Tarsus Pharmaceuticals	3.3601 of 5 stars	$62.48 -4.1%	$90.67 +45.1%	+43.0%	$2.69B	$535.08M	N/A	50
RDY Dr. Reddy's Laboratories	3.2866 of 5 stars	$12.25 -6.8%	$16.90 +38.0%	-5.7%	$10.24B	$3.81B	15.94	27,811	News Coverage Earnings Report Analyst Downgrade
ABVX Abivax	3.2501 of 5 stars	$121.51 -0.5%	$137.15 +12.9%	+1,805.7%	$9.61B	N/A	N/A	61
CYTK Cytokinetics	2.824 of 5 stars	$74.86 +0.4%	$98.55 +31.6%	+144.7%	$9.30B	$88.04M	N/A	250	Analyst Forecast Insider Trade Options Volume Analyst Revision
KRYS Krystal Biotech	2.7264 of 5 stars	$311.12 -0.6%	$324.11 +4.2%	+134.5%	$9.18B	$389.13M	41.64	210	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARS) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. RDY, ABVX, CYTK, KRYS, and PRAX

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Tarsus Pharmaceuticals compare to Abivax?

Summary

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Summary

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Summary

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. RDY, ABVX, CYTK, KRYS, and PRAX

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Which has more volatility and risk, RDY or TARS?

Do institutionals & insiders hold more shares of RDY or TARS?

Is RDY or TARS more profitable?

Which has stronger earnings & valuation, RDY or TARS?

Does the media refer more to RDY or TARS?

Do analysts prefer RDY or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Abivax?

Do analysts recommend ABVX or TARS?

Is ABVX or TARS more profitable?

Which has more risk and volatility, ABVX or TARS?

Does the media favor ABVX or TARS?

Do institutionals and insiders believe in ABVX or TARS?

Which has better valuation and earnings, ABVX or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Which has more risk & volatility, TARS or CYTK?

Do analysts recommend TARS or CYTK?

Is TARS or CYTK more profitable?

Does the media prefer TARS or CYTK?

Do insiders and institutionals have more ownership in TARS or CYTK?

Which has better valuation & earnings, TARS or CYTK?

Summary

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Which has more volatility and risk, KRYS or TARS?

Does the media favor KRYS or TARS?

Is KRYS or TARS more profitable?

Do insiders and institutionals have more ownership in KRYS or TARS?

Do analysts recommend KRYS or TARS?

Which has higher earnings and valuation, KRYS or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Is PRAX or TARS more profitable?

Do institutionals & insiders have more ownership in PRAX or TARS?

Which has more volatility & risk, PRAX or TARS?

Does the media prefer PRAX or TARS?

Do analysts recommend PRAX or TARS?

Which has higher valuation and earnings, PRAX or TARS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools